MedTrace Logo

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

NCT05498051 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-07-07

No results posted yet for this study

Summary

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections

Conditions

  • Colonic Neoplasms
  • Sentinel Lymph Node
  • Fluorescence
  • Colorectal Neoplasms

Interventions

PROCEDURE

Sentinel lymph node identification

Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.

Sponsors & Collaborators

  • Meander Medical Center

    lead OTHER

Principal Investigators

  • Esther Consten, prof. dr. · Meander Medisch Centrum

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-02-01
Completion
2023-06-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05498051 on ClinicalTrials.gov